AbbVie (ABBV) Plans $7.5B Tender Offer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
Go back to AbbVie (ABBV) Plans $7.5B Tender Offer
April 27, 2018 8:10 AM EDT
AbbVie (NYSE: ABBV) today announced that data for elagolix, an investigational, orally administered gonadotropin-releasing hormone (GnRH) receptor antagonist, will be presented at the 2018 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting in Austin, TX.
"We strive to improve care for women living with endometriosis and uterine fibroids," said Dawn Carlson, M.D., M.P.H., vice president, general medicine development. "These presentations highlight safety and efficacy data for elagolix and... More
April 27, 2018 7:49 AM EDT
Deutsche Bank raised its price target on Abbvie (NYSE: ABBV) to $101.00 (from $100.00) while maintaining a Hold rating.
...
More
April 26, 2018 7:48 AM EDT
AbbVie (NYSE: ABBV) reported Q1 EPS of $1.87, $0.08 better than the analyst estimate of $1.79. Revenue for the quarter came in at $7.93 billion versus the consensus estimate of $7.6 billion.
GUIDANCE:
AbbVie sees FY2018 EPS of $7.66-$7.76, versus the consensus of... More
